Micro Developing Active

LLY's retatrutide muestra resultados mixtos del ensayo

Puntuación
0,4
Velocidad
▲ 1,0
Artículos
6
Fuentes
2

Resumen

Un artículo pertenece a esta narrativa si discute los resultados mixtos del ensayo de retatrutida de Eli Lilly and Company (LLY) para el tratamiento de la diabetes tipo 2.

Artículos Relacionados

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster”

Yahoo Finance · Abr 05, 2026
Mixed

Should You Buy Eli Lilly Stock Before April 10?

Nasdaq · Mar 22, 2026
Mixed

Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial

Yahoo Finance · Mar 22, 2026
Bearish

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

Yahoo Finance · Mar 21, 2026
Mixed

Fuentes

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be … Yahoo Finance
1 Reason Eli Lilly Stock Is Still a Buy Nasdaq
Should You Buy Eli Lilly Stock Before April 10? Nasdaq
Eli Lilly and Company (LLY) Announces Positive Topline Results From … Yahoo Finance
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth … Yahoo Finance

Cronología

Última actualización Mar 21, 2026